Back to Journals » OncoTargets and Therapy » Volume 11

ISL1 is upregulated in breast cancer and promotes cell proliferation, invasion, and angiogenesis

Authors Li L, Sun F, Chen X, Zhang M

Received 17 June 2017

Accepted for publication 28 September 2017

Published 14 February 2018 Volume 2018:11 Pages 781—789


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Samir Farghaly

Lin Li,1 Fuwen Sun,2 Xiaoyan Chen,3 Minghui Zhang1

1Department of Imaging, Linyi People’s Hospital of Shandong Province, Linyi, People’s Republic of China; 2Department of Interventional, Affiliated Hospital of Shandong Medical College, Linyi, People’s Republic of China; 3Department of Spine Surgery, Linyi People’s Hospital of Shandong Province, Linyi, People’s Republic of China

Abstract: ISL1 plays a key role in several cancers, including pheochromocytoma, gastrointestinal, pancreatic, and lung tumors and bile duct carcinoma. In order to elucidate the role of ISL1 in breast cancer, we performed quantitative real-time polymerase chain reaction and Western blotting analysis, and we found that ISL1 was upregulated in breast cancer cells and tissues. Moreover, high expression of ISL1 was correlated with tumor size, metastasis, and poor prognosis. Colony formation analysis and CCK-8 analysis revealed that ISL1 facilitated breast cancer cell proliferation. In addition, wound healing analysis and transwell invasion analysis demonstrated that ISL1 played a role in cell migration and invasion. Interestingly, the expression of ISL1 was also associated with the expression of vascular endothelial growth factor (VEGF) in breast cancer, and ISL1 promoted angiogenesis in breast cancer. In conclusion, reducing the expression of ISL1 suppresses proliferation, migration, invasion, and angiogenesis in breast cancer, suggesting that ISL1 might serve as a novel molecular therapy target in breast cancer.

Keywords: ISL1, proliferation, metastasis, angiogenesis, breast cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]